OKYO Pharma Limited
OKYO
$1.57
-$0.11-6.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 39.29% | -7.52% | -35.55% | -40.11% | -44.35% |
| Gross Profit | -39.29% | 7.52% | 35.55% | 40.11% | 44.35% |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.59% | -48.87% | -54.97% | -45.79% | -36.99% |
| Operating Income | 39.59% | 48.87% | 54.97% | 45.79% | 36.99% |
| Income Before Tax | 46.91% | 50.19% | 52.57% | 39.59% | 26.40% |
| Income Tax Expenses | -24.88% | -251.00% | -14,670.54% | -5,198.92% | -2,193.77% |
| Earnings from Continuing Operations | 56.84% | 66.13% | 72.03% | 53.95% | 35.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.84% | 66.13% | 72.03% | 53.95% | 35.62% |
| EBIT | 39.59% | 48.87% | 54.97% | 45.79% | 36.99% |
| EBITDA | 39.60% | 48.88% | 54.98% | 45.79% | 36.99% |
| EPS Basic | 64.72% | 73.78% | 78.76% | 64.78% | 52.78% |
| Normalized Basic EPS | 57.85% | 61.94% | 64.51% | 54.61% | 46.10% |
| EPS Diluted | 64.72% | 73.78% | 78.76% | 64.78% | 52.78% |
| Normalized Diluted EPS | 57.85% | 61.94% | 64.51% | 54.61% | 46.10% |
| Average Basic Shares Outstanding | 24.46% | 29.20% | 34.57% | 35.66% | 36.97% |
| Average Diluted Shares Outstanding | 24.46% | 29.20% | 34.57% | 35.66% | 36.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |